Workflow
Phathom Pharmaceuticals(PHAT) - 2025 Q2 - Quarterly Results

Phathom Pharmaceuticals Second Quarter 2025 Earnings Release Phathom Pharmaceuticals reported strong Q2 2025 results, driven by VOQUEZNA's commercial success, improved financial performance, and key regulatory milestones Business Highlights and Commercial Performance Phathom Pharmaceuticals reported strong commercial momentum for its GI treatment, VOQUEZNA, in Q2 2025, with net revenues reaching $39.5 million. Total prescriptions surpassed 580,000, showing a 49% increase since the previous report. The company has shifted its commercial strategy to focus on high-value prescribers, primarily gastroenterologists (GIs), and maintains robust commercial access with coverage for over 120 million lives VOQUEZNA Commercial Metrics | Metric | Value | Growth | Source Date | | :--- | :--- | :--- | :--- | | Total Prescriptions Filled | > 580,000 | 49% since May 1, 2025 | July 25, 2025 | | Q2 2025 Prescriptions Filled | ~173,000 | 36% QoQ | Q2 2025 | | Unique HCP Prescribers | > 29,300 | 24% since last quarter | July 18, 2025 | - The company has implemented a strategic shift to prioritize gastroenterologists (GIs) in its sales strategy, who currently account for approximately 70% of all filled VOQUEZNA prescriptions5 - VOQUEZNA has commercial coverage for over 120 million lives, with more than half of these requiring only one prior proton pump inhibitor (PPI) step before approval5 Second Quarter 2025 Financial Results In Q2 2025, Phathom's net revenues surged to $39.5 million from $7.3 million in Q2 2024, driven by the VOQUEZNA launch. Operating expenses increased to $94.4 million, primarily due to commercial investments and restructuring charges. However, operating expenses saw a sequential decrease from Q1 2025 due to cost-saving initiatives. The company reported a reduced net loss of $75.8 million compared to $91.4 million in the prior-year period Key Financial Metrics This section details Phathom's Q2 2025 financial performance, highlighting significant increases in net revenues and changes in operating expenses and net loss compared to Q2 2024 Q2 2025 vs Q2 2024 Financial Performance (in millions) | Metric | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | Net Revenues | $39.5 | $7.3 | +$32.2 | | R&D Expenses | $9.1 | $7.4 | +$1.7 | | SG&A Expenses | $85.3 | $75.9 | +$9.4 | | Total Operating Expenses | $94.4 | $83.2 | +$11.2 | | Net Loss | $(75.8) | $(91.4) | +$15.6 (Improved) | | Non-GAAP Adjusted Net Loss | $(56.5) | $(73.3) | +$16.8 (Improved) | - The increase in R&D and SG&A expenses was primarily driven by one-time personnel-related restructuring charges and continued commercial investment in the VOQUEZNA launch7 - Operating expenses decreased sequentially from $103.7 million in Q1 2025 to $94.4 million in Q2 2025, reflecting cost savings from the company's restructuring7 Financial Position and Outlook The company's financial position as of June 30, 2025, is presented, along with its full-year 2025 revenue guidance and future operating expense targets - As of June 30, 2025, the company held $149.6 million in cash and cash equivalents, which is believed to be sufficient to fund operations and achieve profitability in 2026 (excluding stock-based compensation)13 2025 Financial Guidance | Metric | Guidance Range/Target | | :--- | :--- | | Full-Year 2025 Revenue | $165 million to $175 million | | Q3 2025 Non-GAAP Operating Expenses | < $60 million | | Q4 2025 Non-GAAP Operating Expenses | < $55 million | Regulatory Updates and Corporate Developments During the second quarter, Phathom secured a significant regulatory milestone with the FDA updating the Orange Book to reflect 10-year New Chemical Entity (NCE) exclusivity for VOQUEZNA through May 2032, potentially delaying generic entry until 2033. The company also strengthened its leadership by appointing Anne Marie Cook, J.D., as Chief Legal Officer - The FDA updated the Orange Book to grant 10-year New Chemical Entity (NCE) exclusivity for VOQUEZNA tablets, extending market protection through May 20327 - Based on typical ANDA review timelines, the company believes generic competition is unlikely before 20337 - Phathom appointed Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary to strengthen its leadership team7 Financial Statements and Non-GAAP Reconciliation The report includes unaudited condensed financial statements as of June 30, 2025, and for the three and six months then ended. These statements detail the company's balance sheet and statement of operations. A reconciliation of GAAP to non-GAAP financial measures is also provided, adjusting for items like stock-based compensation and non-cash interest expenses to offer a clearer view of ongoing operational performance Condensed Balance Sheets This section provides a snapshot of Phathom's financial position, detailing assets, liabilities, and stockholders' deficit as of June 30, 2025, and December 31, 2024 Condensed Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $149,569 | $297,263 | | Total assets | $250,220 | $378,318 | | Total liabilities | $656,054 | $631,898 | | Total stockholders' deficit | $(405,834) | $(253,580) | Condensed Statements of Operations This section outlines Phathom's operational performance for the three months ended June 30, comparing product revenue, gross profit, operating expenses, and net loss for 2025 and 2024 Statement of Operations - Three Months Ended June 30 (in thousands) | Account | 2025 | 2024 | | :--- | :--- | :--- | | Product revenue, net | $39,503 | $7,324 | | Gross profit | $34,465 | $5,948 | | Total operating expenses | $94,389 | $83,248 | | Loss from operations | $(59,924) | $(77,300) | | Net loss | $(75,810) | $(91,446) | | Net loss per share | $(1.05) | $(1.56) | Reconciliation of GAAP to Non-GAAP Financial Measures This section reconciles GAAP net loss to non-GAAP adjusted net loss for the three months ended June 30, adjusting for non-cash items to provide a clearer view of core operational profitability GAAP to Non-GAAP Net Loss Reconciliation - Three Months Ended June 30 (in thousands) | Account | 2025 | 2024 | | :--- | :--- | :--- | | GAAP net loss | $(75,810) | $(91,446) | | Stock-based compensation expense | $8,272 | $6,099 | | Non-cash interest on revenue interest financing liability | $10,306 | $11,553 | | Interest expense related to amortization of debt discount | $734 | $499 | | Non-GAAP adjusted net loss | $(56,498) | $(73,295) |